Tweet
Future Microbiol
. 2022 Feb 9.
doi: 10.2217/fmb-2022-0014. Online ahead of print.
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Sabine Hazan 1 , Sonya Dave 2 , Anoja W Gunaratne 3 , Sibasish Dolai 3 , Robert L Clancy 3 , Peter A McCullough 4 , Thomas J Borody 3
Affiliations
- PMID: 35135310
- DOI: 10.2217/fmb-2022-0014
Abstract
Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 (ClinicalTrial.gov).
Keywords: COVID; SARS-CoV-2; coronavirus; doxycycline; ivermectin; zinc.